SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Stake in Allurion Technologies
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a shared beneficial ownership of 4.99% of Allurion Technologies, Inc.'s common stock as of January 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd (the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Allurion Technologies, Inc.
- As of January 31, 2025, the Reporting Persons collectively beneficially own 251,742 shares of Allurion Technologies, Inc. common stock.
- This ownership represents 4.99% of the Issuer's outstanding common stock.
- All 251,742 shares beneficially owned by the Reporting Persons are issuable upon the exercise of warrants.
- The percentage of ownership is calculated based on 3,553,191 shares outstanding as of January 20, 2025, plus an additional 1,240,000 shares issued on January 27, 2025, totaling 4,793,191 shares.
- Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and investment power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the Issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: Neutral. The document is a standard regulatory filing disclosing beneficial ownership, providing factual information without expressing positive or negative sentiment about the company's performance or outlook.
Positives
- A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, maintain a substantial stake of 4.99% in Allurion Technologies, Inc., indicating continued investment interest.
- The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive investment approach.
Negatives
- The beneficial ownership is derived from warrants, which, upon full exercise, could lead to dilution for existing shareholders, although the document notes beneficial ownership limitations.
Risks
- The amount of shares issuable upon exercise of warrants beneficially owned by the Reporting Persons are limited due to beneficial ownership limitations applicable to the warrants, which could restrict their ability to fully convert their holdings if it exceeds a certain threshold.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2025-01-20 | Date for 3,553,191 shares outstanding reported in Issuer's prospectus. |
| 2025-01-27 | Date of Issuer's prospectus filing with the SEC and date 1,240,000 shares were issued. |
| 2025-01-28 | Date of Issuer's Form 8-K filing with the SEC reporting 1,240,000 shares issued. |
| 2025-01-31 | Date of event which requires filing of this statement (beneficial ownership snapshot date). |
| 2025-02-07 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Allurion Technologies, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, warrants, institutional investment, SEC filing, ownership disclosure
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.